Driving innovation through collaborative research partnerships with industry.
A proven centre for translational medicine and data-enabled clinical testing and evaluation, Birmingham is a destination of choice for originating and validating healthcare innovations, working in partnership with businesses, academics, clinicians and patients.
We collaborate with organisations of all sizes, from global corporates through to SMEs and start-ups and we tailor each collaboration to meet your specific needs.
Birmingham is the perfect place to invest in life sciences innovations and our extensive experience of working in partnership with industry provides a solid platform for collaboration.
Sitting at the heart of a large, diverse and stable West Midlands population of nearly 6 million, BHP provides a unique healthcare ecosystem, which harnesses the power of existing NHS, academic, citizen and industrial partnerships to deliver innovation in therapies, diagnostics and devices – at pace and at scale.
BHP provides the environment and physical spaces to support businesses and the commercialisation of innovations. From early-stage, fully serviced incubation at the BioHub, acceleration support at the Institute of Translational Medicine (ITM), through to a range of incubation, grow-on and pre-let spaces on the planned Birmingham Life Sciences Park, we deliver the necessary spaces and services to support successful business development and growth.
Through the BHP network, our industry partners will have access to expertise from our world class clinicians, academics and scientists spanning multiple therapeutic areas, such as inflammation, immunology and immunotherapy, oncology and trauma. In addition, we will facilitate access to well curated clinical data and tissue; support identification and testing of new therapeutics and biomarkers in our patient populations; pioneer the design of new clinical trials – integrating biological measures of outcomes with a patient’s perspective – to support innovative medicine; and speed-up the process of drug discovery.
In order to deliver mutually beneficial and highly successful partnerships, we host an impressive portfolio of key facilities in the following areas:
Cell and gene therapies offer ground-breaking opportunities for the treatment of disease and injury. Advanced therapies could generate an estimated £10bn in revenue for the UK – as well as creating 18,000 jobs – by 2035. Regionally, 175 high-value jobs could open in industry and the NHS over the next five years as new therapies, products and services are developed and deployed.
Our clinicians and academics partner industry across a number of advanced therapy facilities (links open in new window):
- Advanced Therapies Facility
- Human Biomaterials Resource Centre
- Microbiome Treatment Centre (Faecal Microbiota Transplant Service)
- Midlands & Wales Advanced Therapy Treatment Centre
Birmingham has one of Europe’s largest clinical trial portfolios, co-ordinated locally and globally. Our population can support projects of significant scale, and our NHS Trusts regularly top the NIHR Research Activity League table for the West Midlands: together, BHP’s NHS members recruited more than 24,000 participants to 617 different studies in 2018/19. University Hospitals Birmingham also featured in the top five Trusts nationwide for research activity in commercial studies, collaborating with industry partners on 119 studies.
Our experts in clinical trials designs and methodology work across two main facilities (links open in new window):
At the heart of one of the UK’s largest clusters of life sciences businesses, BHP’s collaborative ecosystem provides an outstanding environment for academic-led drug discovery and the search for the next generation of therapies.
Supporting this exceptional translational activity are a host of talented, interdisciplinary scientific researchers specialising in pharmaceutical production processes, target and drug discovery, toxicology and companion diagnostics, among many others. They can be found working across of a number of facilities:
We are at the forefront of digital healthcare innovation and have the expertise to help businesses use our technology and data in a meaningful way.
Industry partners working with BHP benefit from safe and secure access to integrated real-world data – from across and beyond our region – coupled with detailed analysis by our experts. This enables a detailed understanding of diseases and treatments at patient and population level.
Our health data expertise can be accessed via (links open in new window):
The University of Birmingham is also part of the Alan Turing Institute partnership.
One of the greatest social changes in the 21st Century will be the ageing of all populations. The number of people over 60 years of age around the globe is 960 million and is expected to rise to 3.1 billion by 2100.
Healthy lifespan is not keeping pace and ageing carries a heightened risk of physical and mental frailty as well as life-threatening and debilitating chronic diseases. Three million people are now experiencing two or more age-related diseases (“multi-morbidity”) such as cancer, diabetes, heart disease, respiratory disease and dementia.
An improvement in healthy life-span will provide very significant societal and individual quality-of-life benefits.
Birmingham hosts impressive infrastructure and assets as well as intellectual leadership in health ageing, including (links open in new window):
- Institute of Inflammation and Ageing
- NIHR Birmingham Biomedical Research Centre for Inflammatory Disease
- MRC-ARUK Centre for Musculoskeletal Ageing Research
- A-TAP (Arthritis Therapy Acceleration Programme) – a joint Birmingham-Oxford programme funded by the Kennedy Institute to speed up the development of new therapies
- Established public and patient involvement cohorts such as the 1,000 Elders and Rheumatology Research Patient Partnership
- Research into trauma-related inflammation through the NIHR-MoD Surgical Reconstruction & Microbiology Research Centre
Our integrated ecosystem allows industry partners to rapidly develop and test new technologies and tools, and see them through to clinical adoption. We offer both the facilities and the expertise to undertake early-stage research, product development and validation – alongside pre-clinical and clinical evaluation.
Facilities in this specialty include (links open in new window):
- Healthcare Technologies Institute (home to the Centre for Custom Medical Devices)
- NIHR Global Health Research Unit on Global Surgery
- NIHR Surgical Reconstruction and Microbiology Research Centre (SRMRC)
- NIHR Trauma Management Med-Tech Co-Operative
Pioneering and life-changing work takes place across a number of leading facilities, which enable productive interactions between clinicians, academics, industry and patients to accelerate the field of personalised, precision medicine. By enabling integrated, multidisciplinary working, BHP helps bring about answers to complex healthcare issues for the direct benefit of people worldwide.
These facilities include (links open in new window):
Both our NHS Trusts benefit from dedicated rare disease facilities – one-stop clinics where patients (with their carers) undergo pre-planned diagnostic tests and see all relevant specialists and the multi-disciplinary team in one visit.
The centres also facilitate the rapid assessment of cost-effective new drugs and medical devices within clinical settings, providing a single point of entry for individuals, organisations and business seeking to maximise biomedical research translation for the benefit of industry, the economy and patients.
More information on these facilities can be found on the following pages (links open in new window):